1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulators
US8168659B2 · kind B2 · utility
0Cited by
0References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 22, 2007 |
| Grant date | May 1, 2012 |
| Priority date | — |
| Expiry date | Jul 3, 2028 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D207/38
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Compounds and pharmaceutical compositions comprising compounds of the Formulaas CB1 receptor inverse agonists useful for reducing body weight in mammals, treating cognitive impairment associated with schizophrenia, and mitigating treatment emergent weight gain observed during treatment with antipsychotics.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.